ReviewExpert opinion on investigational drugs2019
Clinical drug development for dementia with Lewy bodies: past and present.
Review in Expert opinion on investigational drugs, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 45 citations in OpenAlex.
- Phase 2A Learnings Incorporated into RewinD-LB, a Phase 2B Clinical Trial of Neflamapimod in Dementia with Lewy Bodies.The journal of prevention of Alzheimer's disease · 2024Trial
- Long-term effects of cholinesterase inhibitors and memantine on cognitive decline, cardiovascular events, and mortality in dementia with Lewy bodies: An up to 10-year follow-up study.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Lewy body dementia: Overcoming barriers and identifying solutions.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Dementia with Lewy Bodies Drug Therapies in Clinical Trials: Systematic Review up to 2022.Neurology and therapy · 2023Review
- Chemical Knockdown of Phosphorylated p38 Mitogen-Activated Protein Kinase (MAPK) as a Novel Approach for the Treatment of Alzheimer's Disease.ACS central science · 2023Article
- Drug Discovery and Development Targeting Dementia.Pharmaceuticals (Basel, Switzerland) · 2023Review
- The ANeED study - ambroxol in new and early dementia with Lewy bodies (DLB): protocol for a phase IIa multicentre, randomised, double-blinded and placebo-controlled trial.Frontiers in aging neuroscience · 2023Article
- On gaps of clinical diagnosis of dementia subtypes: A study of Alzheimer's disease and Lewy body disease.Frontiers in aging neuroscience · 2023Article
- Lewy Body Dementias: Controversies and Drug Development.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2022Review
- What evidence is there for implicating the brain orexin system in neuropsychiatric symptoms in dementia?Frontiers in psychiatry · 2022Article
- Identification of a Thyroid Hormone Derivative as a Pleiotropic Agent for the Treatment of Alzheimer's Disease.Pharmaceuticals (Basel, Switzerland) · 2021Article
- Phytochemicals as Regulators of Genes Involved in Synucleinopathies.Biomolecules · 2021Review
- A Perspective on Natural and Nature-Inspired Small Molecules Targeting Phosphodiesterase 9 (PDE9): Chances and Challenges against Neurodegeneration.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Screening of small molecules using the inhibition of oligomer formation in α-synuclein aggregation as a selection parameter.Communications chemistry · 2020Article
- Challenges and opportunities for improving the landscape for Lewy body dementia clinical trials.Alzheimer's research & therapy · 2020Review
- P38α MAPK Signaling-A Robust Therapeutic Target for Rab5-Mediated Neurodegenerative Disease.International journal of molecular sciences · 2020Review
- Epigenetics in Lewy Body Diseases: Impact on Gene Expression, Utility as a Biomarker, and Possibilities for Therapy.International journal of molecular sciences · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.